SRR8518228
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.670
- INTERFERON_GAMMA_RESPONSE+0.640
- ALLOGRAFT_REJECTION+0.610
- IL6_JAK_STAT3_SIGNALING+0.590
- INFLAMMATORY_RESPONSE+0.480
- TNFA_SIGNALING_VIA_NFKB+0.470
- COMPLEMENT+0.420
- IL2_STAT5_SIGNALING+0.350
- KRAS_SIGNALING_UP+0.330
- APOPTOSIS+0.190
Top 10 suppressed
- GLYCOLYSIS-0.330
- CHOLESTEROL_HOMEOSTASIS-0.250
- MTORC1_SIGNALING-0.240
- PANCREAS_BETA_CELLS-0.240
- ESTROGEN_RESPONSE_LATE-0.230
- OXIDATIVE_PHOSPHORYLATION-0.210
- SPERMATOGENESIS-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
- ESTROGEN_RESPONSE_EARLY-0.190
- MYOGENESIS-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518387 | — | D | 0.944 |
| 2 | SRR8613774 | — | D | 0.892 |
| 3 | BSR_02_0049_A5_S69 | — | D | 0.876 |
| 4 | SRR8518454 | — | D | 0.856 |
| 5 | TCGA-E9-A1NE-01A-21R-A14M-07 | — | A | 0.854 |
| 6 | TCGA-AR-A0TT-01A-31R-A084-07 | — | D | 0.852 |
| 7 | TCGA-A2-A0ST-01A-12R-A084-07 | — | D | 0.849 |
| 8 | SRR8613712 | — | D | 0.849 |
| 9 | AUR-AFSL-TTM1-A-8-0-R-A741-41 | — | D | 0.846 |
| 10 | SRR8518406 | — | D | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.670 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.640 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.610 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.590 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.350 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |